Agnodice Pharmaceuticals Private Limited
About Agnodice Pharmaceuticals Private Limited
Data last updated:
Agnodice Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 May 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24304MH2020PTC339655.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Mayur Rajnikant Dalal and Pratibha Mayur Dalal.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹58,737, a growth of 12% compared to the previous year. For the same year it recorded a net loss of ₹9,139 (net margin -15.6%) and EBITDA of -₹9,139 (EBITDA margin -15.6%). Revenue has grown at a compounded annual rate (CAGR) of 14% over three years.
Company details
Contact details
Agnodice Pharmaceuticals Private Limited's registered office is in Mumbai, Maharashtra.
- Registered AddressA – 408A Floor 4 Plot 711 A Byculla Services Industries, Dadoji Konddeo Road Ghodapdeo Byculla (E), Mumbai, Maharashtra, India – 400027
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Agnodice Pharmaceuticals Private Limited
FY 2025 filings availableAgnodice Pharmaceuticals Private Limited reported revenue of ₹58,737 (up 12% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 14% over three years, including 12% growth in the latest year. EBITDA rose 60% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹9,139 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹9,139 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -15.6% | ||||
| Net Profit Margin | -15.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Agnodice Pharmaceuticals Private Limited, buy the company report.
Board of directors of Agnodice Pharmaceuticals Private Limited
Agnodice Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mayur Rajnikant Dalal | Director | 06 May 2020 | 6 Years 5 Months | Current |
| Pratibha Mayur Dalal | Director | 06 May 2020 | 6 Years 5 Months | Current |
Peer comparison
Agnodice Pharmaceuticals Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Halcyon Pharmaceuticals Limited | ₹61,632 (FY 2024) | -33.0% | Hisar, Haryana, India | |||
| Enmando Pharmaceuticals Private Limited | ₹61,500 (FY 2024) | -50.0% | Saidulajab, Delhi, India | |||
| Sannolik Pharmaceuticals Private Limited | ₹60,500 (FY 2023) | -69.0% | Gaya, Bihar, India | |||
| Mitosis Pharmaceuticals Private Limited | ₹59,685 (FY 2025) | 186.0% | Govind Nagar, Uttar Pradesh, India | |||
| Nubiotic Pharmaceuticals Private Limited | ₹59,207 (FY 2021) | -57.0% | Patna, Bihar, India | |||
| Agnodice Pharmaceuticals Private Limitedthis company | ₹58,737 (FY 2025) | -₹9,139 | -15.6% | 12.0% | Mumbai, Maharashtra, India | |
| Swadha Pharmaceuticals Private Limited | ₹56,972 (FY 2021) | -14.0% | New Delhi, Delhi, India | |||
| Vemed Pharmaceuticals Private Limited | ₹56,676 (FY 2024) | Vadodara, Gujarat, India | ||||
| Fragliscure Pharmaceuticals Private Limited | ₹56,227 (FY 2025) | 250.0% | Faridabad, Haryana, India | |||
| Willcure Pharmaceuticals Private Limited | ₹56,037 (FY 2025) | -21.0% | Ghaziabad, Uttar Pradesh, India | |||
| Scafell Pharmaceuticals Private Limited | ₹55,745 (FY 2022) | -72.0% | Jharoda Majra, Delhi, India |
To see the full peer comparison of Agnodice Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Agnodice Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Agnodice Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Agnodice Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Agnodice Pharmaceuticals Private Limited has 2 board changes on record since 2020: 2 appointments. The latest: Mayur Rajnikant Dalal was appointed as Director on 06 May 2020.
Frequently asked questions
Agnodice Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 06 May 2020 (6+ years old) and is registered under CIN U24304MH2020PTC339655.
Agnodice Pharmaceuticals has 2 current directors:
- Mayur Rajnikant Dalal - Director
- Pratibha Mayur Dalal - Director
The latest financial statements of Agnodice Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2021 are in the company report.
The CIN (Corporate Identification Number) of Agnodice Pharmaceuticals is U24304MH2020PTC339655. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Agnodice Pharmaceuticals was incorporated on 06 May 2020, making it 6+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Agnodice Pharmaceuticals by revenue are Halcyon Pharmaceuticals Limited, Enmando Pharmaceuticals Private Limited, Sannolik Pharmaceuticals Private Limited, Mitosis Pharmaceuticals Private Limited, Nubiotic Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharmaceuticals).
Mayur Rajnikant Dalal was appointed as Director on 06 May 2020. Pratibha Mayur Dalal was appointed as Director on 06 May 2020.
The registered office of Agnodice Pharmaceuticals is at A – 408A Floor 4 Plot 711 A Byculla Services Industries, Dadoji Konddeo Road Ghodapdeo Byculla E, Mumbai, Maharashtra, India – 400027.
Agnodice Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Agnodice Pharmaceuticals can be reached at its registered office: A – 408A Floor 4 Plot 711 A Byculla Services Industries, Dadoji Konddeo Road Ghodapdeo Byculla E, Mumbai, Maharashtra, India – 400027.
Agnodice Pharmaceuticals is registered under the jurisdiction of the Registrar of Companies (ROC), Mumbai.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
